extract: 2025-05-01-nejm-semaglutide-mash-phase3-liver
Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>
This commit is contained in:
Teleo Agents
parent
458aa7494e
commit
17f98daa43
4 changed files with 48 additions and 1 deletions
|
|
@ -29,6 +29,12 @@ Real-world persistence data from 125,474 commercially insured patients shows the
|
|||
|
||||
The Cell Press review characterizes GLP-1s as marking a 'system-level redefinition' of cardiometabolic management with 'ripple effects across healthcare costs, insurance models, food systems, long-term population health.' Obesity costs the US $400B+ annually, providing context for the scale of potential cost impact. The WHO issued conditional recommendations within 2 years of widespread adoption (December 2025), unusually fast for a major therapeutic category.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-05-01-nejm-semaglutide-mash-phase3-liver]] | Added: 2026-03-15*
|
||||
|
||||
MASH indication adds a third organ-protection pathway (liver, after cardiovascular and kidney), strengthening the multi-indication economic case. However, the Value in Health Medicare study showed only $28M MASH savings—surprisingly small given the 63% clinical resolution rate, likely because MASH progression to transplant takes decades, placing most savings beyond the 10-year budget window.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -30,6 +30,12 @@ For value-based care models and capitated payers, this multi-organ protection cr
|
|||
- Nature Medicine: additive benefits with SGLT2 inhibitors
|
||||
- First GLP-1 to receive FDA indication for CKD in T2D patients
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-05-01-nejm-semaglutide-mash-phase3-liver]] | Added: 2026-03-15*
|
||||
|
||||
NEJM Phase 3 trial adds liver protection as a third major organ system. Semaglutide achieved 62.9% MASH resolution vs 34.3% placebo, with meta-analysis showing reduced risk of major CV events, clinically significant portal hypertension, and all-cause mortality in MASLD/MASH patients. Some hepatoprotective effects operate independently of weight loss, suggesting direct GLP-1 receptor-mediated liver benefits.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -0,0 +1,24 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "glp-1-agonists-resolve-steatohepatitis-in-63-percent-of-mash-patients-through-mechanisms-partially-independent-of-weight-loss.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 1,
|
||||
"kept": 0,
|
||||
"fixed": 1,
|
||||
"rejected": 1,
|
||||
"fixes_applied": [
|
||||
"glp-1-agonists-resolve-steatohepatitis-in-63-percent-of-mash-patients-through-mechanisms-partially-independent-of-weight-loss.md:set_created:2026-03-15"
|
||||
],
|
||||
"rejections": [
|
||||
"glp-1-agonists-resolve-steatohepatitis-in-63-percent-of-mash-patients-through-mechanisms-partially-independent-of-weight-loss.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-15"
|
||||
}
|
||||
|
|
@ -7,9 +7,13 @@ date: 2025-05-01
|
|||
domain: health
|
||||
secondary_domains: []
|
||||
format: paper
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: medium
|
||||
tags: [glp-1, semaglutide, MASH, NASH, liver-disease, organ-protection]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-15
|
||||
enrichments_applied: ["glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -39,3 +43,10 @@ Phase 3 trial of semaglutide 2.4mg in patients with MASH and moderate or advance
|
|||
PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
|
||||
WHY ARCHIVED: Third organ-protection pathway (after CV and kidney) strengthens the case that GLP-1s should be evaluated as multi-organ protective agents, not just weight loss drugs
|
||||
EXTRACTION HINT: The multi-organ protection thesis may justify reframing the existing GLP-1 claim from a weight-loss-economics frame to a metabolic-disease-prevention frame
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Resmetirom (Rezdiffra) was approved for MASH in March 2024
|
||||
- MASH is projected to become the leading cause of liver transplantation
|
||||
- GLP-1 RAs reduce liver fat deposition, improve hepatocellular ballooning, and reduce lobular inflammation per 2025 meta-analysis
|
||||
- Meta-analysis shows GLP-1 RAs associated with reduced risk of major CV events, clinically significant portal hypertension, and all-cause mortality in MASLD/MASH patients
|
||||
|
|
|
|||
Loading…
Reference in a new issue